CalciMedica (CALC) Research & Development (2019 - 2026)
CalciMedica's (CALC) quarterly Research & Development came in at $3.5 million in Q1 2026, down 17.5% YoY from $4.2 million in Q1 2025, and up 12.17% on a QoQ basis from $3.1 million in Q4 2025.
CalciMedica (CALC) Research & Development (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Research & Development data on file, last reported at $3.5 million in Q1 2026.
- Quarterly Research & Development fell 17.5% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.5 million (down 8.01% YoY) and the FY2025 annual result came in at $15.2 million, up 5.22% from the prior year.
- Research & Development rose to $3.5 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $6.5 million in Q1 2023 to a low of $1.2 million in Q3 2022.
- A 5-year average of $3.4 million and a median of $3.5 million in 2026 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development sank 69.06% — and 2023, when it surged 122.83%.
- Tracing CALC's Research & Development over 5 years: stood at $1.9 million in 2022, then surged by 44.75% to $2.8 million in 2023, then surged by 37.71% to $3.8 million in 2024, then decreased by 18.9% to $3.1 million in 2025, then climbed by 12.17% to $3.5 million in 2026.
- The last three Research & Development figures came in at $3.5 million (Q1 2026), $3.1 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | CalciMedica | 9.93 Mn | -8.69 Mn | - | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 3.49 Mn |
| Dec 31, 2025 | 3.11 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 4.16 Mn |
| Mar 31, 2024 | 2.94 Mn |
| Dec 31, 2023 | 2.78 Mn |
| Sep 30, 2023 | 2.77 Mn |
| Jun 30, 2023 | 3.81 Mn |
| Mar 31, 2023 | 6.49 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 2.26 Mn |
| Mar 31, 2022 | 2.93 Mn |
| Dec 31, 2021 | 4.27 Mn |
| Sep 30, 2021 | 4.02 Mn |